relugolix was first described in 2004. it superseded sufugolix (developmental code name tak-013), which was developed by the same researchers. relugolix was approved for the treatment of uterine fibroids in japan on 8 january 2019. it was the second orally active gnrh antagonist to be introduced for medical use, following elagolix (brand name orilissa) in july 2018.